ASE swings to ₹0.67 Cr consolidated profit in Q2 FY27 as revenue grows 31% YoY
revenue +30.78% · margins expanding
₹58.13 Cr
+30.78% YoY
₹0.67 Cr
1.13%
+2.3pp YoY
₹0.09
Ambalal Sarabhai Enterprises reported consolidated revenue of ₹58.13 Cr for Q2 FY27 (quarter ended 30 Sep 2026), up 30.8% YoY from ₹44.45 Cr and up 33.4% QoQ from ₹43.56 Cr. Consolidated PAT turned around to a profit of ₹0.67 Cr against a loss of ₹0.56 Cr in the year-ago quarter — the YoY story is a turnaround, not a growth multiple, since the base was negative. Sequentially, however, PAT fell 83% from ₹3.98 Cr in Q1 FY27, and NPM compressed to roughly 1.1% from 8.7% in Q1 FY27 even as revenue rose, so the YoY turnaround should not be read as momentum — Q1's profitability was not sustained into Q2.
Q2 FY-2027 vs prior quarters
The margin squeeze sits on the operating line: combined segment EBIT fell to ₹2.36 Cr (Pharmaceuticals ₹1.08 Cr on ₹34.89 Cr revenue, Electronics ₹1.28 Cr on ₹23.28 Cr revenue) from ₹5.66 Cr in Q1 FY27, even though revenue was higher this quarter. Purchase of stock-in-trade (₹29.91 Cr) and employee costs (₹8.71 Cr) rose roughly in step with the topline, leaving less drop-through to EBIT; finance costs (₹1.04 Cr) and depreciation (₹1.39 Cr) were broadly stable QoQ. No exceptional items were booked in either the current or year-ago quarter, so the swing from a Q2 FY26 loss to a Q2 FY27 profit is entirely operating-driven, not one-off-driven.
The stock went into the print at ₹36, down 7.7% over the past month of trading.
There is no formal management guidance on record for this company (none in our database, none found via web search), and no brokerage/consensus estimates for this micro-cap turned up in search either — so both vsGuidance and vsStreet are unknown rather than beat/miss. No management press release or commentary accompanies this filing beyond the routine board-outcome letter to BSE. The quarter's other disclosed developments — the trading-window closure from 25 Sep 2026 ahead of results, and the plant visit rescheduled to 1 Dec 2026 — are procedural and do not tie directly to this quarter's numbers. Q1 FY27 had been flagged in our records as "Income Up, PBT Surges"; this quarter's sharp QoQ PBT decline (₹1.32 Cr vs ₹4.68 Cr) shows that surge did not carry forward.
W1
Whether consolidated segment EBIT recovers toward Q1 FY27's ₹5.66 Cr level or the sequential slide continues into Q3 FY27
W2
Standalone parent's recurring losses (₹0.03 Cr this quarter) and whether its other-equity deficit (₹(17.15) Cr as of 30 Sep 2026) narrows
W3
Any disclosures following the plant visit rescheduled to 1 Dec 2026